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shifts on Hgb concentration, and to 
adjust ESA doses with this additional 
variable in mind. 
 In conclusion, the fi ndings of the inter-
esting analysis by Szczech  et al. 1 should 
be a stimulus for further study. But there 
are no immediate clinical implications of 
this observational analysis. Hgb targets 
during ESA therapy for patients with 
CHF or diabetes mellitus should remain 
consistent with current guidelines. An 
Hgb target of 10 – 12 or 11 – 12 g / dl 
remains a reasonable target that balances 
improved quality of life with potential 
cardiovascular risk. 
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 Over the past few decades, there has been 
a substantial decrease in the incidence of 
hepatitis B virus (HBV) infection in hemo-
dialysis patients, probably attri butable to 
screening of blood donors, a decline in 
blood transfusion requirements with 
increased erythropoietin use, and author-
itative guidelines relating to infection con-
trol and vaccination. Despite this progress, 
hemodialysis patients remain at increased 
risk of acquiring HBV because of increased 
exposure to blood products, shared hemo-
dialysis equipment, frequent breaching of 
skin, immunodefi ciency, and continuing 
high prevalence rates of HBV infection 
among hemodialysis populations. 
Although acute infection tends to be mild 
and asymptomatic in dialysis patients, up 
to two-thirds may progress to chronic car-
riage, with signifi cant risk of chronic liver 
disease,  premature death from cirrhosis or 
liver cancer, and nosocomial transmission 
within hemodialysis units. 1,2 
 When available to healthy individuals, 
HBV vaccination is an extremely eff ec-
tive means of disease prevention. Admin-
istration of three doses of 20   g of HBV 
surface antigen (HBsAg) over 6 months 
achieves seroprotection rates of more 
than 90 % . 2 Alternatively, among chronic 
kidney disease (CKD) populations, 
immune responses to HBV vaccination 
are impaired, proportionally to the 
degree of kidney failure. 1 Hence, CKD 
patients experience lower seroconversion 
rates (32 – 80 % ), lower peak antibody titers, 
and shorter durations of seroprotection 
(protective antibody titers maintained in 
50 % of CKD patients compared with 85 % 
of healthy individuals after 1 year). 2,3 
Strategies to improve response rates 
among such patients have included vac-
cination as early as possible in the course 
of renal disease, use of double vaccine 
dose, and a four-dose rather than three-
dose schedule. 1,2 These have yielded 
some, but still suboptimal, improvement, 
achieving response rates of approxi-
mately 70 % . 3 Th us, additional strategies 
to improve vaccination response remain 
an important and as-yet unmet priority. 
 Th e development of protective immu-
nity following administration of vaccine 
requires the interaction of the innate and 
adaptive immune systems (Figure 1). 
Specifi cally, antigen recognition requires 
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antigen-presenting cells of the innate 
immune system (primarily macrophages 
and dendritic cells) to present antigen 
to cells of the adaptive immune system 
(T and B cells). Subsequent T-cell and 
B-cell stimulation and proliferation lead 
to the development of an army of 
immune cells specifi cally designed to 
respond to that antigen. Th e mechanism 
underlying the impaired response to 
vaccination in CKD populations is 
incompletely understood. However, 
 uremia-induced dysfunctional antigen 
presentation is thought to contribute. 3 
 Adjuvants are components added to 
vaccine formulations to enhance the 
immunogenicity of antigens. 3 Aluminum 
is the predominant adjuvant used in many 
currently available vaccines, including the 
standard HBV vaccine ( Table 1 ). Its mode 
of action is incompletely understood, but 
its known effects include enhanced 
uptake of antigen by antigen-presenting-
cells, stimulation of cytokine release, 
and increased antigen-specifi c prolifera-
tion of T cells. 4 
 Surquin and colleagues 5 (this issue) 
report an open, multicenter randomized 
controlled trial comparing the ability of 
two alternative adjuvant systems, HB-
AS04 and HB-AS02, to induce a protective 
HBV antibody response in CKD patients. 
HB-AS04 has previously demonstrated 
the ability to elicit higher and more per-
sistent levels of anti-hepatitis B surface 
antibodies (anti-HBs) in CKD patients 
when compared with double doses of 
standard HBV vaccine, 6,7 leading to its 
licensing for use in CKD patients in 
Europe in 2005. While never tested previ-
ously in CKD patients, HB-AS02 has been 
shown to generate strong and persistent 
humoral and T-cell responses in healthy 
adults, providing the rationale for a com-
parative trial with HB-AS04. 
 HB-AS04 comprises 20   g recom-
binant HBsAg, aluminum phosphate, 
and monophosphoryl lipid ( Table 1 ). 
Monophosphoryl lipid is a purified, 
detoxifi ed derivative of the lipopolysac-
charide molecule of the bacterial wall of 
 Salmonella minnesota , which, like 
lipopolysaccharide, is thought to bind to 
Toll-like receptor 4 on antigen-presenting 
cells. Th is leads to direct antimicrobial 
responses, as well as maturation of 
antigen-presenting cells and their migra-
tion to draining lymph nodes, increased 
expression of costimulatory molecules, 
and release of cytokines required for the 
activation and diff erentiation of T and B 
cells. 8 In contrast, HB-AS02 is an alumi-
num-free preparation containing 20   g 
recombinant HBsAg, monophosphoryl 
lipid, and QS21 ( Table 1 ). QS21 is a highly 
purifi ed immunostimulant extracted from 
the bark of the South American  Quillaja 
saponaria tree. Th e mechanism of action 
of QS21 has not been fully elucidated, but 
 in vitro experiments suggest that it also 
improves antigen presentation. 8 
 Th ree hundred patients who were pre-
dialysis or receiving hemodialysis or peri-



















 Figure 1  |   Hepatitis B virus vaccination. (1) Hepatitis B virus (HBV) vaccine formulation 
containing hepatitis B virus surface antigen (HBsAg), monophosphoryl lipid (MPL) and QS21 is 
administered to the patient. (2) The adjuvant (MPL and QS21) stimulates the immune system. It is 
thought that MPL does this via binding to Toll-like receptor 4 on antigen-presenting cells (APCs), 
which leads to direct antimicrobial responses, as well as maturation and migration of APCs to 
draining lymph nodes, increased expression of co-stimulatory molecules and release of cytokines 
required for the activation and differentiation of T and B cells. QS21 is thought to also improve 
antigen presentation. (3) APC presents HBsAg to T cells. (4) Recognition of HBsAg in the presence 
of costimulation leads to activation and proliferation of  T cells. (5) T cells secrete cytokines that lead 
to proliferation and differentiation of B cells into plasma cells. (6) Plasma cells secrete antibodies to 
HBsAg, thereby providing immunity to HBV.  
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either three doses of HB-AS02 (at 0, 1, and 
6 months) or four doses of HB-AS04 (at 0, 
1, 2, and 6 months). Results showed that 
HB-AS02 was able to induce more rapid 
antibody responses, higher peak antibody 
titers, and prolonged duration of seropro-
tection compared with HB-AS04. Each of 
these improvements has specifi c relevance 
to CKD populations. Rapid seroconver-
sion is clearly benefi cial within the dialysis 
sett ing, as the sooner a protective antibody 
titer is obtained, the lower the cumulative 
risk of infection. Th e duration of protec-
tion afforded by HBV vaccination —
 directly proportional to the peak antibody 
level obtained aft er vaccination 9 — is also 
important given that isolated cases of 
 clinically signifi cant HBV infection have 
been documented in immunocompro-
mised persons with waning anti-HBs 
titers. 1 Given recommendations for 
annual anti-HBs testing of CKD patients, 
and, where relevant, administration of 
booster doses, 1,2 higher initial peak titers 
and increased duration of seroprotec-
tion would decrease the requirement 
for, and the costs associated with, 
booster dosing. 
 The impressive seroprotection rates 
observed in both arms of this trial are of 
interest (anti-HBs >10 IU per liter in >90 % 
of participants in both the HB-AS02 and 
HB-AS04 groups 5 ). Although it is tempt-
ing to ascribe this to increased immuno-
genicity of the vaccine formulations, it 
should be noted that similarly impressive 
seroprotection rates were seen in both the 
experimental and the control (standard 
HBV vaccine) arms of the earlier HB-AS04 
trial (91 % versus 84 % , respectively;  P  =  not 
significant). 6 Consequently, it must be 
considered that the characteristics of these 
studied populations may have diff ered in 
some way from those of more typical CKD 
populations, in whom markedly poorer 
seroconversion responses are observed. 
Particularly, a high proportion of partici-
pants were predialysis in both the earlier 
HB-AS04 versus standard HBV vaccine 
trial 6 and this trial. Additionally, neither 
trial reported on other factors known to 
predict seroconversion, such as dialysis 
adequacy, hemoglobin, serum albumin, or 
erythropoietin-stimulating agent usage. 
 Importantly, Surquin  et al. 5 did not 
demonstrate an increase in overall sero-
protection rate with use of the new vac-
cine formulation (seroprotection achieved 
in 96.4 % compared with 91.8 % of partici-
pants in the HB-AS02 and HB-AS04 
groups, respectively, over the 12 months of 
follow-up; diff erence, 4.55 % , 95 % confi -
dence interval  – 1.25 to 11.22). Similarly, in 
the earlier HB-AS04 trial, there was no 
signifi cant diff erence in overall proportion 
achieving seroprotection with HB-AS04 
compared with standard HBV vaccine. 6 
Th is suggests a similar ability of the newer 
formulations to induce an immune 
response compared with the standard 
HBV vaccine. Although isolated cases of 
HBV infection have been documented in 
immunocompromised persons with anti-
HBs titers     10 IU per liter, it is likely that 
a seroconversion response allows for the 
development of immunological memory 
and subsequent protection in most, as is 
seen in immunocompetent individuals. 
Th is is supported by the rapid anamnestic 
response to booster dosing in those who 
have responded previously, regardless of 
humoral immune status. 1 Thus, while 
more rapid seroconversion and prolonged 
duration of immunity are defi nitely advan-
tageous, the overall ability of an HBV vac-
cine to achieve protective antibody titers 
should remain the primary focus. 
 It is also worth pointing out that other 
HBV vaccination strategies have shown 
promise in CKD populations. In rand-
omized controlled trial settings, both 
intradermal HBV vaccination 10 and the 
addition of granulocyte – macrophage 
colony-stimulating factor (GM-CSF) 11 
have demonstrated improved ability over 
standard HBV vaccination to generate a 
seroprotective antibody response. Further, 
these agents have been tested in cohorts 
comprising purely dialysis patients non-
responsive to primary HBV vaccination. 
Being later in the course of renal disease 
and having already declared themselves as 
belonging to the more immunodefi cient 
group of non-responders, such individu-
als collectively represent a more  ‘ trouble-
some ’ group. Testing the efficacy of 
HB-AS02 in this setting would be of con-
siderable interest. 
 In conclusion, prevention of HBV infec-
tion in CKD populations is an important 
priority, and progress has been made over 
recent decades. However, infection rates 
are still unacceptably high, and further 
work is required. Th e article by Surquin 
 et al. 5 reports an important initiative in 
providing primary HBV vaccination to 
CKD patients. The adjuvanted vaccine 
HB-AS02 shows clear immunological 
advantage with regard to its ability to 
increase speed of seroconversion and dura-
tion of seroprotection, both of which are 
important in CKD populations. However, 
its ability to improve overall seroconversion 
response compared with HB-AS04 or stand-
ard HBV vaccine remains unproven, as does 
its ability to perform in dialysis patients 
non-responsive to primary vaccination. 
Further study of this is required, as are fur-
ther trials of alternative strategies aimed at 
improving vaccination response among 
CKD patient populations ( Figure 1 ). 
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 Table 1  |   Vaccine formulations 
 Composition 
 Standard HBV 
vaccine (Engerix-B)  HB-AS04 (Fendrix)  HB-AS02 
 Recombinant HBV 
surface antigen 
 20   g  20   g  20   g 
 Adjuvant  500   g Al 3  +    500   g Al 3  + ,  50   g 
monophosphoryl lipid 
 50   g monophosphoryl 
lipid, 50   g QS21 
 Excipients  Sodium chloride, 
water 
 Sodium chloride, 
water 
 Oil-in-water emulsion 
 Volume / dose  1.0  ml  0.5  ml  0.5  ml 
 Dose a  Double  Single  Single 
 Schedule a  0, 1, 2, and 6 months  0, 1, 2, and 6 months  0, 1, and 6 months 
 a Dose administered and schedule followed in the HBV vaccination comparative trials in chronic kidney disease populations. 
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